Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
Status:
Withdrawn
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Visual outcomes of the eye with large subretinal hemorrhages (bleeding under the retina) due
to Age-Related Macular Degeneration (AMD) are poor. The Submacular Surgery Trial (SST) showed
that no statistically significant improvement in vision resulted from surgical removal of the
layer of abnormal blood vessels causing the bleeding. However, placement of a gas bubble into
the gel of the eye along with removal of the blood has shown some success. However, this does
not treat the underlying condition of the AMD.
Intravitreal injections (into the gel of the eye) of a drug called Lucentis has been shown to
be highly effective in the treatment of AMD, yet its penetration through areas of thick blood
caused by subretinal hemorrhage is not known.
This study is proposing to treat the AMD causing the subretinal hemorrhage with a vitrectomy
(surgery involving removing the gel inside the eye, and membrane layers of the eye) followed
by Lucentis placed between the layers of the retina and then with or without a gas bubble.
In order to determine if the the subretinal Lucentis alone is beneficial, 5 of the 10
patients enrolled will get a gas bubble and the other 5 will not.